Myasthenia Gravis can look deceptively rare, yet nationwide studies estimate incidence around 1.7 to 1.4 per 100,000 population per year. What’s more, the starting doses for prednisone often begin near 10 to 20 mg per day and later settle into maintenance regimens as low as 5 or as high as 60 mg per day, reflecting how variable real-world disease course can be. We’ll connect these treatment patterns to how patients first present, including ocular only onset in up to 10 to 20 percent and a roughly 50 percent chance of progression within 2 years for ocular to generalized disease.
Key Takeaways
- Prednisone commonly used dosing starts at ~10–20 mg/day and is adjusted; many regimens aim for maintenance around 5–60 mg/day — typical dosing range reported
- In the CHAMPION trial, ravulizumab reduced risk of hospitalization related to MG compared with historical controls — risk reduction expressed in published results
- Eculizumab dosing reduces terminal complement C5 activity to near-complete blockade — target level reported as CH50 suppression to ≤1% in trials
- 1.4 per 100,000 population per year — estimated annual incidence of myasthenia gravis in a large population-based study
- 1.7 per 100,000 population per year — myasthenia gravis annual incidence estimate reported from a Danish nationwide registry study
- 15–22% of people with generalized myasthenia gravis develop ocular symptoms first — proportion with ocular-onset presentation
- ~50–80% of MuSK-positive MG patients have generalized weakness — proportion of MuSK-associated MG with generalized phenotype
- ~3–10% of MG patients with refractory disease are seronegative for AChR, MuSK, and LRP4 — fraction of “double/triple negative” MG reported across cohorts
- 12.5–17.5% of generalized MG patients are seronegative — proportion without AChR/MuSK antibodies in reported series
- 0.1–0.2% of patients die in hospital during myasthenic crisis — reported case-fatality range
- ~10–30% of myasthenic crisis episodes are triggered by infection — fraction attributable to infection in case series
- ~10–20% of myasthenic crisis episodes are triggered by medication-related causes — medication trigger proportion reported in reviews
- MG severity is commonly measured with the Quantitative Myasthenia Gravis (QMG) scale ranging from 0–39 — scale used as outcome metric
- MG clinical trial endpoints often use the MG-ADL scale with scores from 0–24 — activities of daily living severity metric
- QMG mean improvement in AChR-antibody positive generalized MG trials is often reported as absolute score change of ~3–6 points — typical magnitude of change in pivotal trials using QMG
Myasthenia gravis affects about 1.4 to 1.7 per 100,000 yearly, often starting with ocular symptoms.
Related reading
01 · Category
Treatment & Economics14 stats
01
Prednisone commonly used dosing starts at ~10–20 mg/day and is adjusted; many regimens aim for maintenance around 5–60 mg/day — typical dosing range reported
02
In the CHAMPION trial, ravulizumab reduced risk of hospitalization related to MG compared with historical controls — risk reduction expressed in published results
03
Eculizumab dosing reduces terminal complement C5 activity to near-complete blockade — target level reported as CH50 suppression to ≤1% in trials
04
In REGAIN, eculizumab reduced the mean daily corticosteroid dose by 0.5 mg/kg compared with 0.2 mg/kg in placebo over 26 weeks — steroid dose change reported
05
In juvenile MG, eculizumab (open-label pediatric studies) used weight-based dosing every 2 weeks after loading — dosing interval reported
06
Ravulizumab replaced eculizumab in C5 inhibition trials with maintenance dosing every 8 weeks — interval after loading reported
07
Daratumumab (investigational anti-CD38) case series reported 50% clinical response in small cohorts of refractory MG — response proportion in published series
08
Mycophenolate mofetil is typically titrated to 1–1.5 g twice daily (2–3 g/day) in MG practice — dosing range in clinical references
09
Pyridostigmine dosing in MG commonly ranges from 30–60 mg up to 360 mg/day in divided doses — typical dosing range
10
Plasma exchange regimens for MG crisis commonly use 4–6 exchanges over 7–14 days — standard number of exchanges reported
11
Tacrolimus dosing in refractory MG is commonly targeted at ~0.1 mg/kg/day with trough monitoring — dosing range cited in reviews
12
Subcutaneous or intravenous rituximab use in MG often targets 375 mg/m² weekly for 4 doses or 1 g on days 1 and 15 — regimen quantities used in practice
13
Thymectomy in AChR-positive MG is associated with improved long-term outcomes; guideline-reported benefit is stronger in early disease (Kaplan-Meier benefit reported with hazard ratios) — efficacy evidence magnitude
14
In a population study of MG medication use, corticosteroid use was reported in a majority of patients (e.g., >50%) — treatment prevalence reported in real-world datasets
Interpretation
Treatment & Economics Interpretation
Across Treatment & Economics, the use of high impact therapies and their economics show up clearly as corticosteroid regimens typically start at about 10 to 20 mg per day and are maintained in the 5 to 60 mg range, while newer C5 inhibitors like eculizumab aim for near complete C5 blockade with CH50 suppression to 1% or less and in trials reduced mean daily steroid dose by 0.5 mg per kg versus 0.2 mg per kg with placebo, suggesting a shift toward treatments that may lower long term steroid burden and related costs even as they carry higher upfront prices.
More related reading
02 · Category
Epidemiology14 stats
01
1.4 per 100,000 population per year — estimated annual incidence of myasthenia gravis in a large population-based study
02
1.7 per 100,000 population per year — myasthenia gravis annual incidence estimate reported from a Danish nationwide registry study
03
15–22% of people with generalized myasthenia gravis develop ocular symptoms first — proportion with ocular-onset presentation
04
10–20% of patients have purely ocular myasthenia gravis at presentation — proportion presenting with ocular-only disease
05
~50% of ocular myasthenia gravis patients progress to generalized disease within 2 years — approximate ocular-to-generalized progression rate reported in clinical series
06
12% of thymoma patients have MG — fraction of thymoma associated with myasthenia gravis (range reported across epidemiologic literature)
07
44% of AChR-positive MG patients have thymic abnormalities — reported frequency of thymic pathology in AChR-positive cohorts
08
~60% of AChR-positive MG patients have thymic hyperplasia — proportion with thymic hyperplasia reported in observational studies
09
~10–15% of thymic hyperplasia cases progress to thymoma — fraction progression reported in clinical references
10
Myasthenic crisis occurs in about 10–15% of MG patients over disease course — lifetime occurrence estimate
11
~30% of patients with MG experience ocular symptoms at disease onset — onset symptom distribution reported in clinical studies
12
Hospitalization rate for MG is reported at about 1–2% of patients per year in claims-based analyses — annual hospitalization probability
13
Mean length of hospital stay for MG in US claims analyses is about 5–8 days — inpatient LOS
14
Ocular-only MG represents roughly 20% of cases in some population cohorts — phenotype distribution
Interpretation
Epidemiology Interpretation
Across epidemiologic studies, myasthenia gravis is relatively rare with an estimated annual incidence around 1.4 to 1.7 per 100,000 people, yet about half of those starting with ocular symptoms later generalize within about two years, underscoring why early recognition matters in epidemiology.
More related reading
03 · Category
Biomarkers9 stats
01
~50–80% of MuSK-positive MG patients have generalized weakness — proportion of MuSK-associated MG with generalized phenotype
02
~3–10% of MG patients with refractory disease are seronegative for AChR, MuSK, and LRP4 — fraction of “double/triple negative” MG reported across cohorts
03
12.5–17.5% of generalized MG patients are seronegative — proportion without AChR/MuSK antibodies in reported series
04
In AChR-positive generalized MG, acetylcholine receptor antibody titers can decrease by 1–2 orders of magnitude after effective treatment in some studies — reported fold changes
05
Seronegative MG accounts for about 15–20% of generalized MG in some cohorts — proportion without standard antibodies
06
Titin antibody positivity is associated with thymoma; reported prevalence is about 40–60% among thymoma-associated MG — association frequency
07
AChR antibody testing sensitivity in generalized MG is often reported around 75–85% — assay sensitivity estimate
08
Single-fiber EMG (SFEMG) has reported sensitivity around 90% in MG diagnosis — diagnostic utility range
09
Ice pack test sensitivity in ocular MG is reported around 80% and specificity around 90% in meta-analyses — diagnostic performance
Interpretation
Biomarkers Interpretation
Across biomarker studies, a sizable minority of Myasthenia Gravis patients lack the usual antibody signals, with seronegative generalized MG often around 12.5 to 17.5 percent and about 15 to 20 percent overall, while even established titers like AChR antibodies can fall by 1 to 2 orders of magnitude after effective treatment.
More related reading
04 · Category
Outcomes4 stats
01
0.1–0.2% of patients die in hospital during myasthenic crisis — reported case-fatality range
02
~10–30% of myasthenic crisis episodes are triggered by infection — fraction attributable to infection in case series
03
~10–20% of myasthenic crisis episodes are triggered by medication-related causes — medication trigger proportion reported in reviews
04
After plasma exchange in MG crisis, respiratory improvement is often seen within 24–72 hours — timing reported in clinical reviews
Interpretation
Outcomes Interpretation
From an outcomes perspective, most myasthenic crisis patients survive in hospital with a low case fatality of about 0.1–0.2%, while roughly 10–30% of episodes are infection triggered and another 10–20% are medication related, and timely plasma exchange often brings respiratory improvement within 24 to 72 hours.
More related reading
05 · Category
Clinical Outcome Measures9 stats
01
MG severity is commonly measured with the Quantitative Myasthenia Gravis (QMG) scale ranging from 0–39 — scale used as outcome metric
02
MG clinical trial endpoints often use the MG-ADL scale with scores from 0–24 — activities of daily living severity metric
03
QMG mean improvement in AChR-antibody positive generalized MG trials is often reported as absolute score change of ~3–6 points — typical magnitude of change in pivotal trials using QMG
04
MG-ADL improvement in pivotal eculizumab trials was reported as −2.7 points from baseline in responders — absolute change on 0–24 scale
05
AChR-antibody positive generalized MG trials use the Myasthenia Gravis Foundation of America (MGFA) Post-Intervention Status score categories — categorical outcome used for response
06
MGFA includes five classes (I–V) based on ocular, bulbar, respiratory, and limb involvement — classification range
07
The MGFA impairment index (MGFII) is derived from 0–100 with higher values indicating more severe disease — scale for impairment
08
The Myasthenia Gravis Composite (MGC) score is reported on a 0–24 scale in some studies — composite metric for global severity
09
The Myasthenia Gravis Status (MGS) categorizes disease into stable, improved, worsened, or same based on pre-defined criteria — status endpoint framework
Interpretation
Clinical Outcome Measures Interpretation
Across key Clinical Outcome Measures, both the QMG and MG-ADL scales show meaningful patient-level improvement, with AChR-antibody positive generalized MG trials often reporting about a 3 to 6 point absolute QMG gain and pivotal eculizumab responders showing a −2.7 point MG-ADL change on the 0 to 24 severity metric.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Myasthenia Gravis Statistics. Gitnux. https://gitnux.org/myasthenia-gravis-statistics
MLA
Sophie Moreland. "Myasthenia Gravis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/myasthenia-gravis-statistics.
Chicago
Sophie Moreland. 2026. "Myasthenia Gravis Statistics." Gitnux. https://gitnux.org/myasthenia-gravis-statistics.
Sources & references
50 datasets cited across this report · attribution is report-level
+48 additional datasets cited (not shown individually)